Finance
Finance
ื“ืฃ ื”ื‘ื™ืชLEXX โ€ข NASDAQ
Lexaria Bioscience Corp
โ€1.02ย โ€$
ืื—ืจื™ ืฉืขื•ืช ื”ืžืกื—ืจ:
โ€1.07ย โ€$
(4.90%)+0.050
ืกื’ื•ืจ: 14 ื‘ืืคืจืณ, 17:20:00 GMT-4โ€Ž · USD · NASDAQ · ื›ืชื‘ ื•ื™ืชื•ืจ
ืžื ื™ื”ื ื™ื™ืจ ืขืจืš ืฉืจืฉื•ื ื‘ืืจื”"ื‘
ืฉืขืจ ืกื’ื™ืจื” ืงื•ื“ื
โ€0.98ย โ€$
ื˜ื•ื•ื— ื™ื•ืžื™
โ€0.93ย โ€$ - โ€1.06ย โ€$
ื˜ื•ื•ื— ืฉื ืชื™
โ€0.46ย โ€$ - โ€1.69ย โ€$
ืฉื•ื•ื™ ืฉื•ืง
25.39Mโ€ USD
ื ืคื— ืžืกื—ืจ ืžืžื•ืฆืข
185.56Kโ€
ืžื›ืคื™ืœ ืจื•ื•ื—
-
ืชืฉื•ืืช ื“ื™ื‘ื™ื“ื ื“
-
ื‘ื•ืจืกื” ืขื™ืงืจื™ืช
NASDAQ
ื‘ื—ื“ืฉื•ืช
TradingView โ€” Track All Markets
ืœืคื ื™ ื™ื•ื ืื—ื“ (1)
Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings Summary
ื›ืกืคื™ื
ื”ืฆื”ืจืช ื”ื›ื ืกื”
ื”ื›ื ืกื”
ืจื•ื•ื— ื ืงื™
(USD)ื ื•ื‘ืณ 2025ืฉื™ื ื•ื™ ืžืฉื ื” ืœืฉื ื”
ื”ื›ื ืกื”
โ€”โ€”
ื”ื•ืฆืื•ืช ืชืคืขื•ืœื™ื•ืช
1.57Mโ€โ€Ž-45.21%
ืจื•ื•ื— ื ืงื™
โ€Ž-1.60Mโ€41.01%
ืฉื•ืœื™ ืจื•ื•ื— ื ืงื™
โ€”โ€”
ืจื•ื•ื—ื™ื ืœืžื ื™ื”
โ€”โ€”
ืจื•ื•ื— ืœืคื ื™ ืจื™ื‘ื™ืช, ืžื™ืกื™ื, ืคื—ืช ื•ื”ืคื—ืชื•ืช
โ€Ž-1.56Mโ€41.42%
ืฉื™ืขื•ืจ ืžืก ืืคืงื˜ื™ื‘ื™
โ€Ž-0.11%โ€”
ืกืš ื›ืœ ื”ื ื›ืกื™ื
ื—ื‘ื•ืช ื›ื•ืœืœืช
(USD)ื ื•ื‘ืณ 2025ืฉื™ื ื•ื™ ืžืฉื ื” ืœืฉื ื”
ืžื–ื•ืžื ื™ื ื•ื”ืฉืงืขื•ืช ืœื˜ื•ื•ื— ืงืฆืจ
4.42Mโ€โ€Ž-45.50%
ืกืš ื›ืœ ื”ื ื›ืกื™ื
6.05Mโ€โ€Ž-38.22%
ื—ื‘ื•ืช ื›ื•ืœืœืช
1.53Mโ€282.11%
ื”ื•ืŸ ืขืฆืžื™ ื›ื•ืœืœ
4.52Mโ€โ€”
ื”ื•ืŸ ืขื•ืžื“
24.89Mโ€โ€”
ืžื›ืคื™ืœ ื”ื•ืŸ
4.45โ€”
ืชืฉื•ืื” ืขืœ ื”ื ื›ืกื™ื
โ€Ž-76.94%โ€”
ืชืฉื•ืื” ืขืœ ื”ื•ืŸ
โ€Ž-107.23%โ€”
ืฉื™ื ื•ื™ ื‘ืฉื•ื•ื™ ืžื–ื•ืžื ื™ื
(USD)ื ื•ื‘ืณ 2025ืฉื™ื ื•ื™ ืžืฉื ื” ืœืฉื ื”
ืจื•ื•ื— ื ืงื™
โ€Ž-1.60Mโ€41.01%
ืžื–ื•ืžื ื™ื ืžืคืขื™ืœื•ืช ืฉื•ื˜ืคืช
โ€Ž-984.10Kโ€63.90%
ืžื–ื•ืžืŸ ืžื”ืฉืงืขื•ืช
โ€Ž-5.10Kโ€86.51%
ืžื–ื•ืžืŸ ืžืžื™ืžื•ืŸ
3.47Mโ€โ€Ž-20.05%
ืฉื™ื ื•ื™ ื‘ืฉื•ื•ื™ ืžื–ื•ืžื ื™ื
2.48Mโ€57.07%
ืชื–ืจื™ื ืžื–ื•ืžื ื™ื ืคื ื•ื™
โ€Ž-364.91Kโ€79.12%
ืžื™ื“ืข ื›ืœืœื™
ืชืืจื™ืš ื”ืงืžื”
2004
ืืชืจ
lexariabioscience.com
ืขื•ื‘ื“ื™ื
7
ืžื ื™ื•ืช ื ื•ืกืคื•ืช
ืžื ื™ื•ืช ืฉืขืฉื•ื™ื•ืช ืœืขื ื™ื™ืŸ ืื•ืชืš
ื”ืจืฉื™ืžื” ื”ื–ื• ื ื•ืฆืจืช ืžื—ื™ืคื•ืฉื™ื ืื—ืจื•ื ื™ื, ืžื ื™ื™ืจื•ืช ืขืจืš ื‘ืžืขืงื‘ ื•ืžืคืขื™ืœื•ื™ื•ืช ืื—ืจื•ืช. ืžื™ื“ืข ื ื•ืกืฃ

ื›ืœ ื”ื ืชื•ื ื™ื ื•ื”ืžื™ื“ืข ืžืกื•ืคืงื™ื ื‘ืฆื•ืจืชื ื”ืžืงื•ืจื™ืช ืœืžื˜ืจื•ืช ืื™ื ืคื•ืจืžื˜ื™ื‘ื™ื•ืช ืื™ืฉื™ื•ืช ื‘ืœื‘ื“, ื•ืœื ื ื•ืขื“ื• ืœืกืคืง ื™ื™ืขื•ืฅ ื›ืœื›ืœื™ ืื• ืœืžื˜ืจื•ืช ืžืกื—ืจ, ื”ืฉืงืขื”, ืžื™ืกื•ื™, ืžืฉืคื˜, ื—ืฉื‘ื•ื ืื•ืช ืื• ื›ืœ ื™ื™ืขื•ืฅ ืื—ืจ. Google ืื™ื ื” ืžืฆื™ืขื” ื™ื™ืขื•ืฅ ื”ืฉืงืขื•ืช ืื• ื™ื™ืขื•ืฅ ืคื™ื ื ืกื™ ื•ืื™ื ื” ืžื‘ื™ืขื” ืขืžื“ื”, ื”ืžืœืฆื” ืื• ื“ืขื” ื›ืœืฉื”ื™ ื‘ื›ืœ ื”ืงืฉื•ืจ ืœื›ืœ ืื—ืช ืžื”ื—ื‘ืจื•ืช ื”ื›ืœื•ืœื•ืช ื‘ืจืฉื™ืžื” ื–ื•, ืื• ืœื ื™ื™ืจื•ืช ื”ืขืจืš ืฉืžื•ื ืคืงื™ื ืขืœ ื™ื“ื™ ื—ื‘ืจื•ืช ืืœื”. ื™ืฉ ืœื”ืชื™ื™ืขืฅ ืขื ืกื•ื›ืŸ ื”ืžื ื™ื•ืช ืื• ื”ื™ื•ืขืฅ ื”ืคื™ื ื ืกื™ ืฉืœืš ื›ื“ื™ ืœืืžืช ืืช ื”ืชืžื—ื•ืจ ืœืคื ื™ ื‘ื™ืฆื•ืข ืขืกืงืช ืกื—ืจ. ืžื™ื“ืข ื ื•ืกืฃ
ืื ืฉื™ื ื—ื™ืคืฉื• ื’ื
ื—ื™ืคื•ืฉ
ื ื™ืงื•ื™ ื”ื—ื™ืคื•ืฉ
ืกื’ื™ืจืช ื”ื—ื™ืคื•ืฉ
ืืคืœื™ืงืฆื™ื•ืช Google
ื”ืชืคืจื™ื˜ ื”ืจืืฉื™